Full name
A Phase 2b, Multi-centre, Randomized, Partially Placebo-controlled, Double-blind Study to Investigate the Safety and Efficacy of Sequential Therapy With Daplusiran/Tomligisiran Followed by Bepirovirsen in Participants With Chronic Hepatitis B Virus on Background Nucleos(t)Ide Analogue Therapy (B-UNITED)
NCT Number
NCT06537414
Geography
US
Non-US
Locations
Australia, Belgium, Brazil, Canada, China, France, Germany, Greece, Hong Kong, Italy, Japan, Republic of Korea, New Zealand, Singapore, South Africa, Spain, Taiwan, United Kingdom, United States
Primary Endpoints
Number of participants achieving functional cure. Up to 100 Weeks
Order
5
Disease
Version
Phase
2
Status
Recruiting